Premier Biomedical, Inc. (OTCQB: BIEI) announced today the favorable results of initial multi-faceted mouse testing of their patent pending anti-cancer antibody versus commercially available competitive drugs. The Premier Biomedical antibody, PBI-5D3H5, demonstrated superiority based on tumor volume and mouse survivability. Read the full press release here:https://upticknewswire.com/premier-biomedical-anti-cancer-antibody-outperforms-leading-multi-billion-dollar-commercial-cancer-treatments-in-initial-head-to-head-testing-at-a-major-university/